Virometix secures USD 15 million to advance novel pneumococcal vaccine

13.11.2025 15:44, Rita Longobardi

Schlieren-based Virometix, a biotechnology company developing fully synthetic vaccines designed to generate targeted immune responses against infectious diseases and cancer, has raised USD 15 million in a financing round backed by existing shareholders. The new capital will enable the company to advance the clinical development of its lead vaccine candidate, V-212, a serotype-independent pneumococcal vaccine currently in Phase I clinical evaluation.

A Venture Kick winner and Top100 Swiss Startup, Virometix recently completed patient enrollment for the Phase I clinical trial of V-212, a synthetic, peptide-based vaccine designed to prevent Streptococcus pneumoniae infections. The vaccine combines conserved antigenic epitopes from pneumococcal surface proteins with Virometix’s proprietary Synthetic Virus-Like Particle (SVLP) technology, which integrates adjuvant components directly into the vaccine structure. This design removes the need for biological carrier proteins and enables a streamlined synthetic manufacturing process.

The randomized, double-blind, placebo-controlled study (NCT06975319) is being conducted at the Centre for Vaccinology (CEVAC) of Ghent University Hospital with 60 healthy volunteers. Topline safety and immunogenicity results are expected in the first quarter of 2026.

The fresh funding will support the completion of this trial, preparations for a Phase Ib combination study with an approved pneumococcal vaccine, and ongoing optimization of the SVLP platform. Virometix also aims to advance its next-generation pneumococcal vaccine programs toward preclinical development.